Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $100.30 | Total: $501.50 |
| 1 | 10 | $84.96 | Total: $849.60 |
| 1 | 25 | $71.98 | Total: $1,799.50 |
| 1 | 50 | $61.36 | Total: $3,068.00 |
| 1 | 100 | $53.10 | Total: $5,310.00 |
Overview
CSF1R-IN-3 is an orally effective CSF-1R inhibitor with an IC50 value of 2.1 nM. CSF1R-IN-3 has anti-proliferative activity against colorectal cancer cells. CSF1R-IN-3 exhibits anti-tumour effects and immune enhancing effects by inhibiting the migration of macrophages and inducing the reprogramming of M2-type macrophages to M1-type macrophages, thus exhibited activity against colorectal cancer cells.
Chemical Properties
| Molecular Formula | C30H38N8O4 |
| Molecular Weight | 574.67 |
| CAS Numbers | 2760584-90-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CN1CCN(CC(=O)Nc2c(C)[nH]c(C=C3C(=O)Nc4cc(NC(=O)Nc5cc(on5)C(C)(C)C)ccc34)c2C)CC1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Lv Q, et al. Discovery of [Z]-1-[3-[[1H-Pyrrol-2-yl]methylene]-2-oxoindolin-6-yl]-3-[isoxazol-3-yl]urea Derivatives as Novel and Orally Highly Effective CSF-1R Inhibitors for Potential Colorectal Cancer Immunotherapy. J Med Chem. 2021 ; 64[23] 17184-17208.